Top

Published in:

Open Access 01-04-2012 | Original Article

Antihypertensive effect of a fixed-dose combination of losartan /hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study

Authors: Tatsuo Hosoya, Satoru Kuriyama, Iwao Ohno, Tetsuya Kawamura, Makoto Ogura, Masato Ikeda, Masahiro Ishikawa, Fumihiro Hayashi, Tatsuya Kanai, Haruo Tomonari, Michimasa Soejima, Kiyoaki Akaba, Goro Tokudome

Published in: Clinical and Experimental Nephrology | Issue 2/2012

Abstract

Background

Achieving adequate blood pressure (BP) control often requires more than one antihypertensive agent. The purpose of this study was to determine whether a fixed-dose formulation of losartan (LOS) plus hydrochlorothiazide (HCTZ) (LOS/HCTZ) is effective in achieving a greater BP lowering in patients with uncontrolled hypertension.

Methods

The study was a prospective, multicenter, observational trial exploring the antihypertensive effect of a single tablet of LOS 50 mg/HCTZ 12.5 mg. A total of 228 patients whose BP had previously been treated with more than one antihypertensive agents without having achieved BP goal below 130/80 mmHg enrolled in the study.

Results

A significant decrease in systolic and diastolic BP was observed in both clinic and home measurement after switching from the previous treatment to LOS/HCTZ. There was a significant decrease in both B-type natriuretic peptide (BNP) and urinary albumin creatinine (Cr) excretion ratio (ACR), especially in patients with elevated values. In contrast, there was a significant increase in serum Cr concentration in conjunction with a decrease in estimated glomerular filtration rate (eGFR). Overall serum uric acid (UA) concentration increased, whereas in patients with hyperuricemia there was a significant reduction in this value.

Conclusion

Switching to LOS/HCTZ provides a greater reduction in clinic and home BP in patients with uncontrolled hypertension. This combination therapy may lead to cardio-, reno protection and improve UA metabolism.

Available only for authorised users

World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983–92.

Ohkubo T, Obara T, Funahashi J, Kikuya M, Asayama K, Metoki H, Oikawa T, Takahashi H, Hashimoto J, Totsune K, Imai Y. Control of blood pressure as measured at home and office, and comparison with physicians’ assessment of control among treated hypertensive patients in Japan: first report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens Res. 2004;27:755–63.PubMedCrossRef

Waeber B. Achieving blood pressure targets in the management of hypertension. Blood Press Suppl. 2001;2:6–12.PubMedCrossRef

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Committee. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.

Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, on behalf of The Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3–107.

Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sower J. Preserving renal function on adults with hypertension ans diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646–61.PubMedCrossRef

Kita T, Yokota N, Ichiki Y, Ayabe T, Etoh T, Tamaki N, Kato J, Eto T, Kitamura K. One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Hypertens Res. 2010;33:320–5.PubMedCrossRef

Enomoto A, Kimura H, Chairongudua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate exchanger that regulates blood urate levels. Nature. 2002;417:447–52.PubMed

Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URAT-1 (SLC2A9) in humans. J Biol Chem. 2008;283:26834–8.PubMedCrossRef

10.

Frohlich ED, Grim C, Labarthe DR, Maxell MH, Perloff D, Weidman WH. Recommendation for human blood pressure determination by sphygmomanometers. Hypertension. 1988;11:209A–22A.

11.

Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res. 2006;29:143–51.PubMedCrossRef

12.

Stafford RS, Bartholomew LK, Cushman WC, Cutler JA, Davis BR, Dawson G, Einhorn PT, Furberg CD, Piller LB, Pressel SL, Whelton PK. Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med. 2010;170:851–8.PubMedCrossRef

13.

Ando K, Isshiki M, Takahashi K. Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide. Hypertens Res. 2009;32:748–52.PubMedCrossRef

14.

Brown IJ, Tzoulaki I, Candeias V, Elliott P. Salt intakes around the world: implications for public health. Int J Epidemiol. 2009;38:791–813.PubMedCrossRef

15.

Drenjančević-Perić I, Jelaković B, Lombard JH, Kunert MP, Kibel A, Gros M. High-salt diet and hypertension: focus on the renin-angiotensin system. Kidney Blood Press Res. 2011;34:1–11.PubMedCrossRef

16.

Racine N, Hamet P, Sampalis JS, Longo N, Bastien N. A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. J Hum Hypertens. 2010;24:739–48.PubMedCrossRef

17.

Liou YS, Ma T, Tien L, Lin CM, Jong GP. The relationship between antihypertensive combination therapies comprising diuretics and/or beta-blockers and the risk of new onset diabetes: a retrospective longitudinal cohort study. Hypertens Res. 2009;32:496–9.PubMedCrossRef

18.

Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, Perry HM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212–6.PubMedCrossRef

19.

The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.CrossRef

20.

Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28.PubMedCrossRef

21.

Amery A, Brixko P, Clement D, De Schaepdryver A, Fagard R, Forte J, Henry JF, Leonetti G, O’Malley K, Strasser T, Birkenhäger W, Bulpitt C, Deruyttere M, Dollery C, Forette F, Hamdy R, Joossens JV, Lund-Johansen P, Petrie J, Tuomilehto J, Williams B. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet. 1985;325:1349–54.CrossRef

22.

Beckett NS, Ch B, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.PubMedCrossRef

23.

Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.

24.

Ogihara T, Matsuzaki M, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T, for the COPE Trial Group. Prevention of cardiovascular events with calcium antagonist-based combination therapies in patients with hypertension: a randomized controlled trial—combination therapy of hypertension to prevent cardiovascular events (COPE) trial (abstract). Presented at the International Society of Hypertension in Vancouver, 2010.

25.

Mann SJ. The silent epidemic of thiazide-induced hyponatremia. J Clin Hypertens. 2008;10(6):477–84.CrossRef

26.

Uzu T, Sakaguchi M, Yokomaku Y, Kume S, Kanasaki M, Isshiki K, Araki S, Sugimoto T, Koya D, Haneda M, Kashiwagi A. Effect of high salt intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. Clin Exp Nephrol. 2009;13:300–6.PubMedCrossRef

27.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.PubMedCrossRef

28.

Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.PubMedCrossRef

29.

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Snapinn SM, Wan Y, Lyle PA. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care. 2006;29:595–600.PubMedCrossRef

30.

Matsui Y, Eguchi K, Ishikawa J, Shimada K, Kario K. Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker. Am J Hypertens. 2010. doi:10.1038/ajh.2010.240.

31.

Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving H-H, Grobbee DE, Shahnas S, Zeeuw ME, Heerspink HJL. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan trial. Hypertension. 2011;58:2–7.PubMedCrossRef

Title: Antihypertensive effect of a fixed-dose combination of losartan /hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study
Authors: Tatsuo Hosoya
Satoru Kuriyama
Iwao Ohno
Tetsuya Kawamura
Makoto Ogura
Masato Ikeda
Masahiro Ishikawa
Fumihiro Hayashi
Tatsuya Kanai
Haruo Tomonari
Michimasa Soejima
Kiyoaki Akaba
Goro Tokudome
Publication date: 01-04-2012
Publisher: Springer Japan
Published in: Clinical and Experimental Nephrology / Issue 2/2012
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-011-0564-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Antihypertensive effect of a fixed-dose combination of losartan /hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2012

Oligomeganephronia in an adult without end stage renal failure

Glomerular collapse in a direct topographic relationship with patchy cortical infarction in a native nephrectomy specimen

A case of acute renal failure after exercise with renal hypouricemia demonstrated compound heterozygous mutations of uric acid transporter 1

A treatment dilemma in adult immunoglobulin A nephropathy: what is the appropriate target, preservation of kidney function or induction of clinical remission?

Gene polymorphisms contributing to hypertension in immunoglobulin A nephropathy

Plasma neutrophil gelatinase-associated lipocalin clearance during venovenous hemodiafiltration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page